Abstract
AIDS remains a major global health concern. Despite a number of therapeutic advancements, there is still an urgent need to develop a new class of therapy for human immunodeficiency virus (HIV). Here, it was shown that 1'S-1'-acetoxychavicol acetate (ACA), a small molecular compound isolated from the rhizomes of Alpinia galanga, inhibited Rev transport at a low concentration by binding to chromosomal region maintenance 1 and accumulating full-length HIV-1 RNA in the nucleus, resulting in a block in HIV-1 replication in peripheral blood mononuclear cells. Additionally, ACA and didanosine acted synergistically to inhibit HIV-1 replication. Thus, ACA may represent a novel treatment for HIV-1 infection, especially in combination with other anti-HIV drugs.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Active Transport, Cell Nucleus / drug effects
-
Alpinia / chemistry*
-
Anti-HIV Agents / isolation & purification
-
Anti-HIV Agents / pharmacology*
-
Base Sequence
-
Benzyl Alcohols
-
Cell Line
-
Drug Evaluation, Preclinical
-
Gene Products, rev / metabolism*
-
HIV Infections / drug therapy
-
HIV Infections / virology
-
HIV-1 / drug effects*
-
HIV-1 / genetics
-
HIV-1 / physiology
-
Humans
-
In Vitro Techniques
-
Leukocytes, Mononuclear / drug effects
-
Leukocytes, Mononuclear / virology
-
Phytotherapy
-
Plant Extracts / isolation & purification
-
Plant Extracts / pharmacology
-
RNA, Viral / genetics
-
RNA, Viral / metabolism
-
Terpenes / isolation & purification
-
Terpenes / pharmacology*
-
Virus Replication / drug effects
-
rev Gene Products, Human Immunodeficiency Virus
Substances
-
Anti-HIV Agents
-
Benzyl Alcohols
-
Gene Products, rev
-
Plant Extracts
-
RNA, Viral
-
Terpenes
-
rev Gene Products, Human Immunodeficiency Virus
-
1'-acetoxychavicol acetate